Gerstmann–Sträussler–Scheinker disease (GSS) is a rare, inherited neurodegenerative disorder belonging to the prion diseases. It is associated with disease-causing variants in the PRNP gene and typically produces gradually worsening balance and coordination, followed by other neurological impairments, often including dementia. Its characteristic pathological feature is the accumulation of abnormal prion protein in amyloid plaques within the brain. Compared with many other human prion diseases, GSS usually progresses over a longer period, commonly several years.
Cause and inheritance
GSS is associated with pathogenic variants in PRNP, the gene encoding prion protein. The normal protein is present in several tissues and is particularly abundant in the nervous system. In prion disease, an abnormally folded form promotes the conversion of additional prion protein into abnormal conformations. Accumulation of these proteins is associated with neuronal damage and progressive neurological dysfunction.
The best-known GSS-associated mutation is P102L, a substitution of leucine for proline at position 102 of prion protein. Other PRNP variants are associated with GSS or overlapping inherited prion-disease phenotypes. The relationship between a particular variant and its clinical presentation is not always one-to-one: symptoms, age at onset, and duration can differ even among affected members of the same family.
Inheritance is autosomal dominant. A person carrying a heterozygous disease-causing variant has a 50% probability of transmitting it in each pregnancy, regardless of the child’s sex. Inheriting the variant does not specify the age at which symptoms will appear. Penetrance and the extent of age-related risk depend on the variant.
An apparently negative family history does not necessarily exclude an inherited prion disorder. Possible explanations include incomplete family information, relatives dying before symptom onset, or earlier cases receiving a different diagnosis.
Clinical features and course
The most characteristic initial manifestation is progressive ataxia, particularly difficulty maintaining balance and walking steadily. This reflects prominent involvement of the cerebellum and its connections. Symptoms often begin in middle adulthood, although the reported age range is broad.
Clinical features may include:
- Unsteady gait, falls, and impaired limb coordination.
- Dysarthria, producing slurred or poorly coordinated speech.
- Abnormal eye movements.
- Changes in reflexes, muscle stiffness, or weakness.
- Impaired position or vibration sensation in some forms.
- Progressive difficulties with memory, judgment, or other cognitive functions.
- Swallowing impairment and increasing dependence in advanced disease.
The order and prominence of these features vary. Some affected people have a predominantly cerebellar syndrome for years before substantial cognitive decline develops; others have earlier cognitive, sensory, or movement abnormalities.
Progression is generally slower than in typical sporadic Creutzfeldt–Jakob disease (CJD). A course of approximately two to ten years is often described, but shorter and longer courses occur. The disease is ultimately fatal.
Neuropathology
The hallmark of GSS is the presence of prion-protein amyloid plaques, often with a multicentric appearance, in the cerebellum and other brain regions. Amyloid consists of proteins assembled into abnormal fibrillar deposits.
Associated abnormalities include neuronal loss and reactive changes in supporting glial cells. Spongiform change—the microscopic vacuolation characteristic of many prion diseases—can occur but may be less prominent than in CJD. Some genetic forms also show additional protein deposits, including tau-related abnormalities.
These findings help distinguish GSS from other inherited prion disorders, although pathological and clinical boundaries overlap. Classification therefore draws on the combination of genetic, clinical, and tissue findings rather than on any single symptom.
Diagnosis
Diagnosis combines the clinical course, neurological examination, family history, and molecular genetic testing. Identification of a recognized pathogenic PRNP variant in a person with a compatible neurological syndrome can establish a genetic prion-disease diagnosis. A variant of uncertain significance does not, by itself, establish GSS.
Other investigations help characterize the disorder and assess alternative explanations:
- Magnetic resonance imaging: may show cerebellar or more widespread brain atrophy. The diffusion abnormalities associated with typical CJD may be absent.
- Electroencephalography: can reveal nonspecific abnormalities; periodic complexes characteristic of some CJD cases are not a reliable feature of GSS.
- Cerebrospinal fluid testing: markers of neuronal injury and prion-seeding assays may contribute information, but their performance differs across prion-disease subtypes.
Real-time quaking-induced conversion, or RT-QuIC, detects prion-seeding activity. Although highly useful in diagnosing several forms of prion disease, its diagnostic sensitivity is less consistent in GSS. A negative result therefore does not exclude the disease.
Histopathological examination, most often performed after death, can demonstrate the characteristic plaques and define the pathological phenotype. Brain biopsy is not a routine diagnostic requirement.
The differential diagnosis includes hereditary spinocerebellar ataxias, other inherited prion diseases, and acquired causes of progressive ataxia or cognitive decline.
Management
There is no established treatment that stops or reverses GSS. Care is supportive and addresses neurological symptoms, functional impairment, communication, swallowing, and the consequences of increasing dependence.
Multidisciplinary care may involve physical therapy, occupational therapy, speech and swallowing assessment, nutritional support, and palliative care. Symptom-directed medicines may be used for particular complications, but they do not remove the underlying prion process.
Genetic counseling is relevant to affected families because predictive testing can identify a familial pathogenic variant before symptoms appear. Such testing has implications for psychological well-being, family relationships, reproductive decisions, and privacy. A positive predictive result generally cannot determine an individual’s precise age at onset or future disease course.
Transmission and infection control
Although prions can transmit disease under particular exposure conditions, GSS is primarily an inherited disorder, not an illness spread through ordinary social contact. There is no evidence of transmission through routine caregiving, touching, or sharing a household.
Prion-containing nervous-system tissue presents a different issue. Prions resist many conventional disinfection and sterilization methods, so procedures involving potentially infectious tissue require specialized infection-control protocols.
History and epidemiology
The disorder takes its name from Josef Gerstmann, Ernst Sträussler, and Ilya Scheinker, who described the characteristic familial illness and neuropathology in 1936. Its genetic basis became clearer with the identification of disease-associated PRNP variants in the late twentieth century.
GSS is exceptionally rare and has been documented in families from multiple geographical regions. Reliable population estimates are difficult because of its rarity, variation in presentation, and possible misclassification as other hereditary ataxias or dementias.